Effect of EECP on Anterior Ischemic Optic Neuropathy

Anterior Ischemic Optic Neuropathy Clinical Trial

— AION  

Official title:

Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01768260
• Other study ID #: Eye EECP-1
• Status: Recruiting
• Phase: N/A
• First received: January 8, 2013
• Last updated: March 29, 2017
• Start date: December 2012
• Est. completion date: March 2018

Study information

• Verified date: March 2017
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: Yan Zhang, MD
• Phone: 862087755766
• Email: Zhyan3[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.

Description:

Patients with Anterior Ischemic Optic Neuropathy are randomized into two groups: one group receive standard medical treatment for ischemic optic neuropathy, the other group plus EECP therapy besides standard medical treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: March 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• ischemic optic neuropathy

• within 1 month

Exclusion Criteria:

• Hemorrhagic disease

• thrombophlebitis or infection lesions

• severe hypertensive patients

• Atrial fibrillation

• Aortic regurgitation

Related Conditions & MeSH terms

• Anterior Ischemic Optic Neuropathy
• Ischemia
• Optic Nerve Diseases
• Optic Neuropathy, Ischemic
• Peripheral Nervous System Diseases

Intervention

Device:
• Enhanced external counterpulsation
EECP is performed for 1 hours every day, for a total of 36 hours.

Drug:
• Aspirin
Standard drug therapy

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Sun Yat- sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

References & Publications (1)

Werner D, Michalk F, Harazny J, Hugo C, Daniel WG, Michelson G. Accelerated reperfusion of poorly perfused retinal areas in central retinal artery occlusion and branch retinal artery occlusion after a short treatment with enhanced external counterpulsation. Retina. 2004 Aug;24(4):541-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Central retinal artery flow velocity		7 weeks
Primary	visual acuity		7 weeks
Secondary	Ophthalmic artery blood flow velocity		7 weeks